Technical Analysis for BNTC - Benitec Biopharma Limited

Grade Last Price % Change Price Change
grade D 5.0616 -4.14% -0.22
BNTC closed up 8.87 percent on Wednesday, February 19, 2020, on 1.31 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical BNTC trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish -4.14%
Crossed Above 50 DMA Bullish -4.14%
Stochastic Buy Signal Bullish -4.14%
Wide Bands Range Expansion -4.14%
Oversold Stochastic Weakness -4.14%
50 DMA Resistance Bearish 4.36%
1,2,3 Pullback Bullish Bullish Swing Setup 4.36%
Calm After Storm Range Contraction 4.36%
Outside Day Range Expansion 4.36%
Wide Bands Range Expansion 4.36%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Biotechnology Biopharmaceutical Biology Pain Chemotherapy Genetics Gene Expression Genetic Engineering Hepatitis B HIV/Aids Wet Age Related Macular Degeneration Huntington's Disease RNA Retinitis Pigmentosa Hepatitis C Clinical Applications Oculopharyngeal Muscular Dystrophy Chronic And Life Threatening Conditions

Is BNTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.0
52 Week Low 4.13
Average Volume 93,047
200-Day Moving Average 8.06
50-Day Moving Average 4.92
20-Day Moving Average 5.04
10-Day Moving Average 5.35
Average True Range 0.83
ADX 43.8
+DI 45.04
-DI 8.42
Chandelier Exit (Long, 3 ATRs ) 9.13
Chandelier Exit (Short, 3 ATRs ) 6.89
Upper Bollinger Band 6.26
Lower Bollinger Band 3.83
Percent B (%b) 0.6
BandWidth 48.32
MACD Line 0.04
MACD Signal Line 0.06
MACD Histogram -0.0208
Fundamentals Value
Market Cap 54.15 Million
Num Shares 10.3 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -10.15
Price-to-Sales 3.15
Price-to-Book 1.63
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.38
Resistance 3 (R3) 6.31 5.88 6.19
Resistance 2 (R2) 5.88 5.60 5.91 6.13
Resistance 1 (R1) 5.58 5.43 5.73 5.65 6.07
Pivot Point 5.15 5.15 5.23 5.18 5.15
Support 1 (S1) 4.85 4.87 5.00 4.92 4.49
Support 2 (S2) 4.42 4.70 4.45 4.43
Support 3 (S3) 4.12 4.42 4.37
Support 4 (S4) 4.19